-+ 0.00%
-+ 0.00%
-+ 0.00%

Celularity closes biomaterials asset sale and license deal with NexGel for $13.3 million

PUBT·04/21/2026 12:31:07
Listen to the news
Celularity closes biomaterials asset sale and license deal with NexGel for $13.3 million
  • Celularity closed an asset transaction with NexGel covering commercial and other assets tied to its biomaterials product portfolio.
  • Consideration totaled $13.3 million, including $8.3 million cash at closing.
  • Deal also included a $5 million convertible promissory note from NexGel.
  • Celularity may receive up to $20 million in future milestone payments tied to net sales thresholds.
  • Proceeds enabled retirement of nearly $13 million of debt, shifting focus toward longevity-focused therapeutics and manufacturing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604210830PRIMZONEFULLFEED9693731) on April 21, 2026, and is solely responsible for the information contained therein.